{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:27:03Z","timestamp":1793798823434,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.amjms.2026.10.001","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:18:52Z","timestamp":1790954332000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of pulmonary hypertension in interstitial lung disease without access to inhaled treprostinil: A case series from a resource-limited setting"],"prefix":"10.1016","author":[{"given":"P\u0131nar Ak\u0131n","family":"Kabalak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"S\u00f6yler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba \u0130nal","family":"Cengiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dclk\u00fc","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.amjms.2026.10.001_bib0001","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","article-title":"Epidemiology and treatment of pulmonary arterial hypertension","volume":"14","author":"Lau","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.amjms.2026.10.001_bib0002","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.healun.2020.09.011","article-title":"Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry","volume":"39","author":"Hoeper","year":"2020","journal-title":"J Heart Lung Transpl"},{"issue":"12","key":"10.1016\/j.amjms.2026.10.001_bib0003","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.healun.2019.09.010","article-title":"Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial","volume":"38","author":"McLaughlin","year":"2019","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.amjms.2026.10.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01633-2023","article-title":"Phenotypes in pulmonary hypertension","volume":"64","author":"Weatherald","year":"2024","journal-title":"Eur Respir J"},{"issue":"38","key":"10.1016\/j.amjms.2026.10.001_bib0005","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjms.2026.10.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01200-2024","article-title":"Pulmonary hypertension associated with lung diseases","volume":"64","author":"Shlobin","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2026.10.001_bib0007","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/MCP.0000000000000790","article-title":"Pulmonary hypertension in intersititial lung disease: screening, diagnosis and treatment","volume":"27","author":"Behr","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.amjms.2026.10.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2026.10.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2026.10.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01483-2021","article-title":"Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry","volume":"58","author":"Olsson","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2026.10.001_bib0011","doi-asserted-by":"crossref","first-page":"084","DOI":"10.1164\/rccm.202411-2157OC","article-title":"Serial pulmonary hemodynamics in patients with IPFL listed for lung transplantat","volume":"211","author":"Nathan","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjms.2026.10.001_bib0012","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/resp.14378","article-title":"Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: a bayesian retrospective observational cohort study","volume":"28","author":"Dawes","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.amjms.2026.10.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02414-2022","article-title":"Long\u2013term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open\u2013label extension study","volume":"61","author":"Waxman","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2026.10.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02651-2025","article-title":"Pulmonary hypertension associated with interstitial lung disease: state\u2013of\u2013the\u2013art review","author":"Raghu","year":"2026","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2026.10.001_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2026.1798347","article-title":"Latin American expert opinion paper on the diagnosis and treatment of pulmonary hypertension associated with interstitial lung disease","volume":"13","author":"Lescano","year":"2026","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.amjms.2026.10.001_bib0016","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s12325-026-03508-4","article-title":"Screening for pulmonary hypertension in interstitial lung disease: preliminary results from the PHINDER study","volume":"43","author":"Zisman","year":"2026","journal-title":"Adv Ther"},{"key":"10.1016\/j.amjms.2026.10.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70316","article-title":"An abbreviated assessment tool for detection of pulmonary hypertension in patients with interstitial lung disease","volume":"16","author":"Dagher","year":"2026","journal-title":"Pulm Circ"},{"issue":"26","key":"10.1016\/j.amjms.2026.10.001_bib0018","article-title":"Characterization of CT imaging\u2013derived pulmonary vascular abnormalities associated with pulmonary hypertension in chronic lung disease","volume":"S0012\u20133692","author":"Garcia","year":"2026","journal-title":"Chest"},{"issue":"26","key":"10.1016\/j.amjms.2026.10.001_bib0019","article-title":"Imaging\u2013based pulmonary hypertension phenotypes in connective tissue disease\u2013related interstitial lung disease","volume":"S0012\u20133692","author":"Khan","year":"2026","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.amjms.2026.10.001_bib0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.chest.2025.07.4107","article-title":"On behalf of the pulmonary vascular disease (PVD) section. Pulmonary hypertension associated with interstitial lung diseases","volume":"169","author":"Jose","year":"2026","journal-title":"Chest"},{"key":"10.1016\/j.amjms.2026.10.001_bib0021","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"4_MeetingAbstracts","key":"10.1016\/j.amjms.2026.10.001_bib0023","article-title":"A randomized, double\u2013blind, placebo\u2013controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis","volume":"132","author":"Krowka","year":"2007","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.amjms.2026.10.001_bib0024","doi-asserted-by":"crossref","first-page":"00659","DOI":"10.1183\/23120541.00659-2023","article-title":"Severe pulmonary hypertension\u2013interstitial lung disease presenting as right ventricular failure: stabilisation with intravenous prostacyclin and maintenance with inhaled prostacyclin","volume":"10","author":"Parikh","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.amjms.2026.10.001_bib0026","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1183\/09059180.00006711","article-title":"Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease","volume":"20","author":"Howard","year":"2011","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.amjms.2026.10.001_bib0022","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/life14091068","article-title":"A case of interstitial lung disease\u2013related pulmonary hypertension successfully treated with inhaled iloprost","volume":"14","author":"Jang","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.amjms.2026.10.001_bib0025","first-page":"1","article-title":"Inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease: advances, challenges, and future directions","author":"Riou","year":"2026","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.amjms.2026.10.001_bib0028","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00172-2024","article-title":"Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results","volume":"63","author":"Nathan","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2026.10.001_bib0029","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.healun.2021.02.006","article-title":"Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: a post hoc subgroup analysis of the RISE\u2013IIP study","volume":"40","author":"Nathan","year":"2021","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.amjms.2026.10.001_bib0030","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1183\/13993003.02307-2014","article-title":"Severe pulmonary hypertension in lung disease: phenotypes and response to treatment","volume":"46","author":"Brewis","year":"2015","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.amjms.2026.10.001_bib0031","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1164\/rccm.202412-2371OC","article-title":"Hemodynamics and phosphodiesterase\u20135 inhibitor treatment associated with survival in pulmonary hypertension in interstitial lung disease: a PVRI GoDeep META\u2013REGISTRY analysis","volume":"211","author":"Yogeswaran","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjms.2026.10.001_bib0032","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12890-016-0207-3","article-title":"Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study","volume":"16","author":"Takahashi","year":"2016","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.amjms.2026.10.001_bib0033","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijcard.2007.04.084","article-title":"Pulmonary hypertension in rheumatoid arthritis-relation with the duration of the disease","volume":"127","author":"Udayakumar","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjms.2026.10.001_bib0034","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.3390\/jcm14062029","article-title":"Review of the diagnosis and management of pulmonary hypertension associated with interstitial lung disease (ILD-PH)","volume":"14","author":"Kattih","year":"2025","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.amjms.2026.10.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.resinv.2026.101453","article-title":"Early risk response to vasodilators and outcomes in interstitial lung disease associated pulmonary hypertension","volume":"64","author":"Teramachi","year":"2026","journal-title":"Respir Investig"},{"key":"10.1016\/j.amjms.2026.10.001_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02233-2025","article-title":"Prognostic factors in interstitial lung disease-associated pulmonary hypertension: data from the HYPID cohort and the french pulmonary hypertension registry","author":"Diesler","year":"2026","journal-title":"Eur Respir J"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962926003666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962926003666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:40:44Z","timestamp":1793796044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962926003666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"alternative-id":["S0002962926003666"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2026.10.001","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of pulmonary hypertension in interstitial lung disease without access to inhaled treprostinil: A case series from a resource-limited setting","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2026.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Southern Society for Clinical Investigation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}